A5103215673- Health Systems, Economic Evaluations, Quality of Life
- Lipoproteins and Cardiovascular Health
- Lung Cancer Diagnosis and Treatment
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Pharmaceutical Economics and Policy
- Health and Medical Research Impacts
- Multiple Sclerosis Research Studies
- Systemic Lupus Erythematosus Research
- Pediatric Pain Management Techniques
- Inflammatory Bowel Disease
Novartis (United Kingdom)
2022-2023
University of York
2023
University of Maryland, College Park
2023
Merck (Germany)
2021
Merck Serono (Switzerland)
2020
Texas A&M University
2015
Abstract Background The treatment landscape for advanced non-small cell lung cancer (aNSCLC) has evolved rapidly since immuno-oncology (IO) therapies were introduced. This study used recent data to assess real-world patterns and clinical outcomes in aNSCLC the United Kingdom. Methods Electronic prescribing records of treatment-naive patients starting first-line (1 L) between June 2016 March 2018 (follow-up until December 2018) Kingdom assessed retrospectively. Patient characteristics...
Aims: Model how moving from current disease-modifying drug (DMD) prescribing patterns for relapsing-remitting multiple sclerosis (RRMS) observed in the United Kingdom (UK) to based on patient preferences would impact health outcomes over time.Materials and methods: A cohort-based Markov model was used measure effect of DMDs long-term individuals with RRMS. Data a discrete choice experiment were estimate market shares (i.e. preference shares). These real-world UK calculate behavior relapses,...
Abstract Background: The treatment landscape for advanced non-small cell lung cancer (aNSCLC) has evolved rapidly since immuno-oncology (IO) therapies were introduced. This study used recent data to assess real-world patterns and clinical outcomes in aNSCLC the United Kingdom. Methods: Electronic prescribing records of treatment-naive patients starting first-line (1L) between June 2016 March 2018 (follow-up until December 2018) Kingdom assessed retrospectively. Patient characteristics...
To estimate the 12-month probabilities of major adverse cardiovascular events (MACE) and non-cardiovascular death in patients with atherosclerotic disease (ASCVD) elevated low-density lipoprotein cholesterol (LDL-C). A retrospective database analysis. UK primary care. Patients were selected from Clinical Practice Research Datalink (Aurum) linked to Hospital Episode Statistics inpatient Office National mortality datasets. an ASCVD diagnosis between 01 January 2010 31 May 2018 LDL-C ≥2.6...
Studies utilising genotyping methods report the prevalence of familial hypercholesterolaemia to be as high one in 137 adult population.